Firebrick Pharma announced that the European Patent Office has accepted the company’s patent application covering the use of povidone-iodine nasal sprays, including Firebrick’s Nasodine, for the reduction of viral load of SARS-CoV-2 in the nose and for prophylactic use against the virus. Individual European countries can now grant the patent.
According to Firebrick, the US, Mexico, Australia, and South Africa have already granted patents covering these formulations for this purpose. The company cited results from trials of Nasodine in patients with COVID-19 which it says demonstrated complete clearance of the virus after 3 days of treatment.
Ininitially, Firebrick developed Nasodine for the treatment of the common cold in Australia; however, The TGA refused to approve the nasal spray for that indication, and in January 2024, the company said that it was no longer seeking approval of that application. Firebrick has since launched Nasodine as an OTC “nasal hygiene” product in the US and as a germicidal product in Singapore.
Read the Firebrick Pharma press release
